C4 Therapeutics (CCCC) Total Current Liabilities (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Total Current Liabilities of $27.2 million for Q1 2026, down 33.25% year-over-year from $40.8 million in Q1 2025, and down 17.51% quarter-over-quarter from $33.0 million in Q4 2025.
C4 Therapeutics (CCCC) Total Current Liabilities (2019 - 2026) Analysis & Trends
C4 Therapeutics' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $27.2 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 33.25% year-over-year to $27.2 million; the TTM figure through Mar 2026 stood at $27.2 million (down 33.25% YoY), while the FY2025 annual figure was $33.0 million, down 26.88% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $27.2 million, down from $33.0 million in the prior quarter.
- The five-year high for Total Current Liabilities was $55.0 million in Q1 2024, with the low at $27.2 million in Q1 2026.
- The 5-year median for Total Current Liabilities is $44.5 million (2025), against an average of $42.5 million.
- The sharpest annual moves came in 2024 and 2026: Total Current Liabilities jumped 43.02% in 2024, then sank 33.25% in 2026.
- C4 Therapeutics' Total Current Liabilities stood at $44.5 million in 2022, then declined by 4.0% to $42.8 million in 2023, then grew by 5.64% to $45.2 million in 2024, then fell by 26.88% to $33.0 million in 2025, then slipped by 17.51% to $27.2 million in 2026.
- Business Quant data shows CCCC's Total Current Liabilities at $27.2 million in Q1 2026, $33.0 million in Q4 2025, and $35.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | 48.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.25 Mn |
| Mar 31, 2026 | 27.25 Mn |
| Dec 31, 2025 | 33.03 Mn |
| Sep 30, 2025 | 35.95 Mn |
| Jun 30, 2025 | 44.46 Mn |
| Mar 31, 2025 | 40.82 Mn |
| Dec 31, 2024 | 45.18 Mn |
| Sep 30, 2024 | 43.29 Mn |
| Jun 30, 2024 | 54.20 Mn |
| Mar 31, 2024 | 55.02 Mn |
| Dec 31, 2023 | 42.77 Mn |
| Sep 30, 2023 | 30.27 Mn |
| Jun 30, 2023 | 48.24 Mn |
| Mar 31, 2023 | 39.38 Mn |
| Dec 31, 2022 | 44.55 Mn |
| Sep 30, 2022 | 45.27 Mn |
| Jun 30, 2022 | 46.15 Mn |
| Mar 31, 2022 | 46.99 Mn |
| Dec 31, 2021 | 51.25 Mn |
| Sep 30, 2021 | 48.69 Mn |